Jpmorgan Chase & CO Corcept Therapeutics Inc Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 290,775 shares of CORT stock, worth $21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
290,775
Previous 259,902 11.88%
Holding current value
$21 Million
Previous $13.1 Million 153.6%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$49.85 - $114.22 $1.54 Million - $3.53 Million
30,873 Added 11.88%
290,775 $33.2 Million
Q4 2024

Feb 12, 2025
BUY
$44.66 - $60.85 $305,117 - $415,727
6,832 Added 2.7%
259,902 $13.1 Million
Q3 2024

Dec 26, 2024
BUY
$29.51 - $46.26 $2.26 Million - $3.54 Million
76,573 Added 43.38%
253,070 $11.7 Million
Q3 2024

Nov 08, 2024
BUY
$29.51 - $46.26 $2.26 Million - $3.54 Million
76,573 Added 43.38%
253,070 $11.7 Million
Q2 2024

Dec 26, 2024
SELL
$22.21 - $34.48 $1.7 Million - $2.64 Million
-76,573 Reduced 30.26%
176,497 $5.73 Million
Q2 2024

Aug 12, 2024
SELL
$22.21 - $34.48 $379,213 - $588,711
-17,074 Reduced 8.82%
176,497 $5.73 Million
Q1 2024

Dec 26, 2024
SELL
$21.1 - $27.46 $1.26 Million - $1.63 Million
-59,499 Reduced 23.51%
193,571 $4.88 Million
Q1 2024

May 10, 2024
SELL
$21.1 - $27.46 $126,874 - $165,116
-6,013 Reduced 3.01%
193,571 $4.88 Million
Q4 2023

Dec 26, 2024
SELL
$24.82 - $32.88 $1.33 Million - $1.76 Million
-53,486 Reduced 21.13%
199,584 $6.48 Million
Q4 2023

Feb 12, 2024
BUY
$24.82 - $32.88 $173,740 - $230,160
7,000 Added 3.63%
199,584 $6.48 Million
Q3 2023

Nov 14, 2023
SELL
$21.97 - $33.8 $657,386 - $1.01 Million
-29,922 Reduced 13.45%
192,584 $5.25 Million
Q2 2023

Aug 11, 2023
SELL
$21.44 - $25.15 $1.46 Million - $1.71 Million
-68,086 Reduced 23.43%
222,506 $4.95 Million
Q1 2023

May 18, 2023
BUY
$19.2 - $24.47 $2.17 Million - $2.77 Million
113,105 Added 63.73%
290,592 $6.29 Million
Q1 2023

May 11, 2023
SELL
$19.2 - $24.47 $1.25 Million - $1.59 Million
-64,959 Reduced 26.79%
177,487 $3.84 Million
Q4 2022

Feb 13, 2023
BUY
$19.95 - $29.96 $208,178 - $312,632
10,435 Added 4.5%
242,446 $4.92 Million
Q3 2022

Nov 14, 2022
BUY
$24.7 - $29.12 $81,411 - $95,979
3,296 Added 1.44%
232,011 $5.95 Million
Q2 2022

Aug 11, 2022
BUY
$17.33 - $25.3 $218,947 - $319,640
12,634 Added 5.85%
228,715 $5.44 Million
Q1 2022

May 11, 2022
BUY
$16.53 - $25.21 $83,245 - $126,957
5,036 Added 2.39%
216,081 $4.87 Million
Q4 2021

Feb 10, 2022
SELL
$17.1 - $23.34 $5.36 Million - $7.32 Million
-313,577 Reduced 59.77%
211,045 $4.18 Million
Q3 2021

Nov 12, 2021
BUY
$19.68 - $22.53 $10.3 Million - $11.8 Million
524,622 New
524,622 $10.3 Million

Others Institutions Holding CORT

# of Institutions
470
Shares Held
82.8M
Call Options Held
489K
Put Options Held
1.02M
View Full List

About CORCEPT THERAPEUTICS INC

CORT Quotes by TradingView
  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $7.72B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email